Developer docs
API playgroundTry for free, no card

Search company profiles

Ubiquigent

Full company profile

uuid0009jfp

Namestring
Ubiquigent
Legal namestring
MRC PPU (Medical Research Council Protein Phosphorylation Unit)
Websiteurl
ubiquigent.com
Company typeenum
Private
Founded yearint
2026
Descriptiontext

Ubiquigent (operating commercially as "Ubiquigent Plus") is a UK-based life sciences research tools and services provider, incorporated in 2009 and headquartered at the University of Dundee in Scotland. The company operates as a commercial brand under the MRC Protein Phosphorylation Unit (MRC PPU), a UK government-funded research body, and benefits from institutional affiliation with the Medical Research Council and the University of Dundee. Its primary customers are academic and industrial life science researchers focused on the ubiquitin-proteasome system, protein phosphorylation, and kinase biology.

The company's product portfolio consists of two interconnected lines. First, it sells high-quality, validated research reagents for ubiquitin and phosphorylation research through an expanded catalogue distributed via its own website and the parent MRC PPU Reagents platform. Second, it offers specialized profiling and assay development services, including mass spectrometry-based deubiquitylating enzyme (DUB) profiling, E3 ligase and E2 profiling, kinase inhibitor screening, and the proprietary KiPIK method for kinase identification. These services are accessed via a network of dedicated sister sites (ubiquitylation.bio, dub-screen.mrc.ac.uk, kinase-screen.mrc.ac.uk, kipik.dundee.ac.uk) and email enquiry through the parent MRC PPU inbox.

Ubiquigent's revenue model combines one-time reagent sales with professional services revenue from bespoke profiling engagements. Distribution is direct-to-consumer via website and email, with no disclosed enterprise contracts or named customers. The company is privately held under a government research parent, has secured one disclosed equity round in 2013 ($804,727 from IP Group, Scottish Enterprise, and the Scottish Investment Bank) alongside non-dilutive grants from Innovate UK (2018) and UK Research and Innovation (2021), and operates with a small team of 1–10 employees under a leadership structure comprising CEO Jason Mundin, Founder & Managing Director Jason Brown, Chairman Mark Treherne, and Chief Scientific Officer Sheelagh Frame.

Short descriptiontext

Ubiquigent is a UK-based life sciences tools provider, operating under the MRC Protein Phosphorylation Unit at the University of Dundee, that sells validated ubiquitin and phosphorylation research reagents and offers specialized profiling services (DUB, E3/E2 ligase, kinase, and KiPIK kinase identification) to academic and industrial researchers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDundee, United Kingdom
HQ citystring
Dundee
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ubiquitin research reagents, drug discovery services, enzyme profiling assays, kinase inhibitor screening, phosphorylation reagents
Industry4 codes
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Drug Discovery Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Research Reagents Sales
TypeOne Time License
Description

Sale of high quality, validated reagents for ubiquitin and phosphorylation research through an expanded catalogue at lower prices

ubiquigent.com
2DUB Profiling Services
TypeProfessional Services
Description

Mass spectroscopy-based DUB profiling service for researchers studying deubiquitylating enzymes

ubiquigent.com
3E3/E2 Ligase Profiling Services
TypeProfessional Services
Description

Profiling services for E3 ligases and E2 enzymes involved in ubiquitin cascade research

ubiquigent.com
4Kinase Profiling Services
TypeProfessional Services
Description

Screening and profiling services for kinase inhibitors and kinase identification using KiPIK method

ubiquigent.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1Ubiquitylation Reagents
Description

Curated subset of reagents from MRC PPU Reagents and Services specifically selected for ubiquitin researchers.

ubiquigent.com
+3 more records
Core offering1 text field

Ubiquigent provides the research community with reagents, kits, and drug discovery, assay development and compound profiling services focused on the ubiquitin system and protein phosphorylation. Its offerings include validated ubiquitylation reagents, mass spectrometry-based DUB (deubiquitylating enzyme) profiling, E3/E2 ligase profiling, kinase inhibitor screening, and the proprietary KiPIK kinase identification method.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Reagents available at lower prices compared to previous offering
Product overview1 text field

Ubiquigent Plus is a unified platform for ubiquitin research reagents and services. The core offering includes Ubiquigent Plus itself, complemented by sister-site offerings: Ubiquitylation Reagents (curated reagent catalogue), DUB Profiling (mass spectrometry-based deubiquitylation analysis), E3 Ligase Profiling (E3/E2 enzyme profiling), Kinase Profiling (kinase inhibitor screening), and KiPIK (kinase identification method). All services are accessed through the parent organization MRC PPU Reagents and Services at Dundee University.

Product and service6 records
1Ubiquigent Plus Reagents and Services Platform
CategoryResearch Reagents and Services Platform
Description

Primary platform providing high quality, validated reagents for ubiquitin research with an expanded catalogue and lower pricing, including many phosphorylation reagents. For academic and industrial life science researchers.

2Ubiquitylation Reagents
CategoryResearch Reagents
Description

A curated reagent catalogue from MRC PPU Reagents and Services specifically selected for ubiquitin researchers, covering protein ubiquitylation research tools.

3DUB Profiling Service
CategoryDrug Discovery Profiling Services
Description

Mass spectrometry-based deubiquitylation profiling service for analysing DUB enzyme activity, identifying and characterising deubiquitylating enzymes. For academic and industrial life science researchers.

4E3 Ligase Profiling Service
CategoryDrug Discovery Profiling Services
Description

Service for profiling E3 ligases with E2 profiling also available as part of the ubiquitin cascade research toolkit. Enquiries managed via MRC PPU Reagents.

5Kinase Profiling Service
CategoryDrug Discovery Profiling Services
Description

Kinase screening service for finding and testing kinase inhibitors, supporting protein phosphorylation research linked to ubiquitin studies.

6KiPIK Kinase Identification
CategoryDrug Discovery Profiling Services
Description

A novel method for kinase identification developed by the MRC PPU at the University of Dundee, offered as a standalone profiling/identification service.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership2 partners
1MRC PPU (Medical Research Council Protein Phosphorylation Unit)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

MRC PPU is the parent organization of Ubiquigent, providing institutional affiliation with the Medical Research Council and access to research expertise. Ubiquigent operates as part of MRC PPU Reagents and Services.

ubiquigent.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Ubiquigent is located at Dundee University and benefits from the academic research environment. The partnership provides access to world-class research facilities and expertise in protein phosphorylation and ubiquitination.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Sigma-Aldrich/Merck sells an enormous life sciences research reagent catalogue, including kinase and ubiquitin-related tools, and competes broadly with Ubiquigent Plus on validated reagent quality and breadth.

TypeBroad incumbent
Description

Thermo Fisher is the dominant life sciences tools company selling reagents, kits, and mass spectrometry-based proteomics services across most research areas, including the ubiquitin and kinase space Ubiquigent serves.

TypeDirect peer
Description

LifeSensors is the most direct competitor - it specializes in ubiquitin and ubiquitin-like (UBL) pathway research reagents, profiling services, and tools for protein degradation studies, directly overlapping Ubiquigent's niche.

TypeBroad incumbent
Description

Promega supplies a broad range of life science research reagents, assay kits, and drug discovery tools (including for protein degradation research), overlapping Ubiquigent's reagent and services offering at much larger scale.

TypeDirect peer
Description

BPS Bioscience provides recombinant enzymes, assay kits, and drug discovery services across ubiquitin-related targets (E3 ligases, DUBs) and kinases, overlapping with both Ubiquigent's reagent and profiling service businesses.

TypeDirect peer
Description

Reaction Biology offers kinase profiling services (including the famous HotSpot kinase assay) and broader enzyme/cro services, directly comparable to Ubiquigent's Kinase Profiling offering.

TypeBroad incumbent
Description

CST is a major research antibody and reagent company with strong coverage of ubiquitination, phosphorylation, and cell signaling pathways, competing with Ubiquigent in the validated-reagent segment.

TypeBroad incumbent
Description

Bio-Techne's Tocris brand is a leading supplier of life science research reagents, including kinase inhibitors and tools for cell signaling research, directly competitive with Ubiquigent Plus reagent catalogue but at much broader scale.

TypeEmerging player
Description

Cayman Chemical supplies biochemical research tools, assay kits, and inhibitor libraries including kinase and ubiquitin-related products, offering a comparable though broader-purposed catalogue to academic and pharma researchers.

TypeDirect peer
Description

Eurofins Discovery / DiscoverX offers kinase, protease, and other enzyme profiling services along with cell-based assays, directly comparable to Ubiquigent's profiling services portfolio.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ubiquigent

Drug Discovery Servicesubiquigent.com

Ubiquigent is a UK-based life sciences tools provider, operating under the MRC Protein Phosphorylation Unit at the University of Dundee, that sells validated ubiquitin and phosphorylation research reagents and offers specialized profiling services (DUB, E3/E2 ligase, kinase, and KiPIK kinase identification) to academic and industrial researchers.

What Ubiquigent does

Ubiquigent (operating commercially as "Ubiquigent Plus") is a UK-based life sciences research tools and services provider, incorporated in 2009 and headquartered at the University of Dundee in Scotland. The company operates as a commercial brand under the MRC Protein Phosphorylation Unit (MRC PPU), a UK government-funded research body, and benefits from institutional affiliation with the Medical Research Council and the University of Dundee. Its primary customers are academic and industrial life science researchers focused on the ubiquitin-proteasome system, protein phosphorylation, and kinase biology.

The company's product portfolio consists of two interconnected lines. First, it sells high-quality, validated research reagents for ubiquitin and phosphorylation research through an expanded catalogue distributed via its own website and the parent MRC PPU Reagents platform. Second, it offers specialized profiling and assay development services, including mass spectrometry-based deubiquitylating enzyme (DUB) profiling, E3 ligase and E2 profiling, kinase inhibitor screening, and the proprietary KiPIK method for kinase identification. These services are accessed via a network of dedicated sister sites (ubiquitylation.bio, dub-screen.mrc.ac.uk, kinase-screen.mrc.ac.uk, kipik.dundee.ac.uk) and email enquiry through the parent MRC PPU inbox.

Ubiquigent's revenue model combines one-time reagent sales with professional services revenue from bespoke profiling engagements. Distribution is direct-to-consumer via website and email, with no disclosed enterprise contracts or named customers. The company is privately held under a government research parent, has secured one disclosed equity round in 2013 ($804,727 from IP Group, Scottish Enterprise, and the Scottish Investment Bank) alongside non-dilutive grants from Innovate UK (2018) and UK Research and Innovation (2021), and operates with a small team of 1–10 employees under a leadership structure comprising CEO Jason Mundin, Founder & Managing Director Jason Brown, Chairman Mark Treherne, and Chief Scientific Officer Sheelagh Frame.

Ubiquigent firmographics

Firmographics
Name
Ubiquigent
Legal name
MRC PPU (Medical Research Council Protein Phosphorylation Unit)
Website
https://ubiquigent.com
Company type
Private
Founded year
2026
Operating status
Operating
Headcount range
1–10 employees
Short description
Ubiquigent is a UK-based life sciences tools provider, operating under the MRC Protein Phosphorylation Unit at the University of Dundee, that sells validated ubiquitin and phosphorylation research reagents and offers specialized profiling services (DUB, E3/E2 ligase, kinase, and KiPIK kinase identification) to academic and industrial researchers.
Ownership category
akta.pro rank

Ubiquigent industry classification

Industry
Product category
Drug Discovery Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Ubiquitin research reagents
  • Drug discovery services
  • Enzyme profiling assays
  • Kinase inhibitor screening
  • Phosphorylation reagents

Where Ubiquigent is headquartered

Location

Headquarters

HQ city
Dundee
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Ubiquigent business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Research Reagents Sales: Sale of high quality, validated reagents for ubiquitin and phosphorylation research through an expanded catalogue at lower prices
  2. DUB Profiling Services: Mass spectroscopy-based DUB profiling service for researchers studying deubiquitylating enzymes
  3. E3/E2 Ligase Profiling Services: Profiling services for E3 ligases and E2 enzymes involved in ubiquitin cascade research
  4. Kinase Profiling Services: Screening and profiling services for kinase inhibitors and kinase identification using KiPIK method

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Ubiquigent product offering

Product offering

Core offering

Ubiquigent provides the research community with reagents, kits, and drug discovery, assay development and compound profiling services focused on the ubiquitin system and protein phosphorylation. Its offerings include validated ubiquitylation reagents, mass spectrometry-based DUB (deubiquitylating enzyme) profiling, E3/E2 ligase profiling, kinase inhibitor screening, and the proprietary KiPIK kinase identification method.

Product overview

Ubiquigent Plus is a unified platform for ubiquitin research reagents and services. The core offering includes Ubiquigent Plus itself, complemented by sister-site offerings: Ubiquitylation Reagents (curated reagent catalogue), DUB Profiling (mass spectrometry-based deubiquitylation analysis), E3 Ligase Profiling (E3/E2 enzyme profiling), Kinase Profiling (kinase inhibitor screening), and KiPIK (kinase identification method). All services are accessed through the parent organization MRC PPU Reagents and Services at Dundee University.

Differentiator

Problem solved

Functional benefit

Brands

  • Ubiquitylation Reagents: Curated subset of reagents from MRC PPU Reagents and Services specifically selected for ubiquitin researchers.
  • Deubiquitylation (DUB) Profiling
  • E3 Ligase Profiling
  • KiPIK

Products and services

  • Ubiquigent Plus Reagents and Services Platform Primary platform providing high quality, validated reagents for ubiquitin research with an expanded catalogue and lower pricing, including many phosphorylation reagents. For academic and industrial life science researchers.
  • Ubiquitylation Reagents A curated reagent catalogue from MRC PPU Reagents and Services specifically selected for ubiquitin researchers, covering protein ubiquitylation research tools.
  • DUB Profiling Service Mass spectrometry-based deubiquitylation profiling service for analysing DUB enzyme activity, identifying and characterising deubiquitylating enzymes. For academic and industrial life science researchers.
  • E3 Ligase Profiling Service Service for profiling E3 ligases with E2 profiling also available as part of the ubiquitin cascade research toolkit. Enquiries managed via MRC PPU Reagents.
  • Kinase Profiling Service Kinase screening service for finding and testing kinase inhibitors, supporting protein phosphorylation research linked to ubiquitin studies.
  • KiPIK Kinase Identification A novel method for kinase identification developed by the MRC PPU at the University of Dundee, offered as a standalone profiling/identification service.

Quantifiable outcome

  • Reagents available at lower prices compared to previous offering

Companies that use Ubiquigent

Customer profile

Segments2 records

Ideal customer profiles2 records

Ubiquigent technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Ubiquigent partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • MRC PPU (Medical Research Council Protein Phosphorylation Unit)coreStrategic or Co-development PartnerMRC PPU is the parent organization of Ubiquigent, providing institutional affiliation with the Medical Research Council and access to research expertise. Ubiquigent operates as part of MRC PPU Reagents and Services.
  • Dundee University (University of Dundee)coreStrategic or Co-development PartnerUbiquigent is located at Dundee University and benefits from the academic research environment. The partnership provides access to world-class research facilities and expertise in protein phosphorylation and ubiquitination.

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Ubiquigent competitors and assessment

Company assessment

Broad incumbents

  • Merck (Sigma-Aldrich): Sigma-Aldrich/Merck sells an enormous life sciences research reagent catalogue, including kinase and ubiquitin-related tools, and competes broadly with Ubiquigent Plus on validated reagent quality and breadth.
  • Thermo Fisher Scientific: Thermo Fisher is the dominant life sciences tools company selling reagents, kits, and mass spectrometry-based proteomics services across most research areas, including the ubiquitin and kinase space Ubiquigent serves.
  • Promega: Promega supplies a broad range of life science research reagents, assay kits, and drug discovery tools (including for protein degradation research), overlapping Ubiquigent's reagent and services offering at much larger scale.
  • Cell Signaling Technology (CST): CST is a major research antibody and reagent company with strong coverage of ubiquitination, phosphorylation, and cell signaling pathways, competing with Ubiquigent in the validated-reagent segment.
  • Bio-Techne (Tocris): Bio-Techne's Tocris brand is a leading supplier of life science research reagents, including kinase inhibitors and tools for cell signaling research, directly competitive with Ubiquigent Plus reagent catalogue but at much broader scale.

Direct peers

  • LifeSensors: LifeSensors is the most direct competitor - it specializes in ubiquitin and ubiquitin-like (UBL) pathway research reagents, profiling services, and tools for protein degradation studies, directly overlapping Ubiquigent's niche.
  • BPS Bioscience: BPS Bioscience provides recombinant enzymes, assay kits, and drug discovery services across ubiquitin-related targets (E3 ligases, DUBs) and kinases, overlapping with both Ubiquigent's reagent and profiling service businesses.
  • Reaction Biology: Reaction Biology offers kinase profiling services (including the famous HotSpot kinase assay) and broader enzyme/cro services, directly comparable to Ubiquigent's Kinase Profiling offering.
  • Eurofins Discovery (DiscoverX): Eurofins Discovery / DiscoverX offers kinase, protease, and other enzyme profiling services along with cell-based assays, directly comparable to Ubiquigent's profiling services portfolio.

Emerging players

  • Cayman Chemical: Cayman Chemical supplies biochemical research tools, assay kits, and inhibitor libraries including kinase and ubiquitin-related products, offering a comparable though broader-purposed catalogue to academic and pharma researchers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Ubiquigent social profiles

Digital presence

Ubiquigent financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ubiquigent leadership team

Management profile

Number of profiles

Profiles4 records

Ubiquigent funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ubiquigent M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ubiquigent

What does Ubiquigent do?

Ubiquigent provides the research community with reagents, kits, and drug discovery, assay development and compound profiling services focused on the ubiquitin system and protein phosphorylation. Its offerings include validated ubiquitylation reagents, mass spectrometry-based DUB (deubiquitylating enzyme) profiling, E3/E2 ligase profiling, kinase inhibitor screening, and the proprietary KiPIK kinase identification method.

Is Ubiquigent a public or private company?

Ubiquigent is a private company. It is classified as state government owned and is currently operating.

When was Ubiquigent founded?

Ubiquigent was founded in 2026. It employs 1 to 10 people.

Where is Ubiquigent based?

Ubiquigent is headquartered in Dundee, United Kingdom, in the Europe region.

How does Ubiquigent make money?

Four revenue lines are on record. Research Reagents Sales are the primary driver. The others are DUB Profiling Services, E3/E2 Ligase Profiling Services and kinase Profiling Services.

Who are Ubiquigent's main competitors?

Broad incumbents on record are Merck (Sigma-Aldrich), Thermo Fisher Scientific, Promega, Cell Signaling Technology (CST) and Bio-Techne (Tocris). Direct peers are LifeSensors, BPS Bioscience, Reaction Biology and Eurofins Discovery (DiscoverX). Cayman Chemical is listed as an emerging player.

Does Ubiquigent have an API?

No public API is recorded for Ubiquigent.

What industry is Ubiquigent in?

Ubiquigent's product category is Drug Discovery Services. Its primary akta.pro industry code is HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes), with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
News-MedicalUbiquigent partners with Alleo Labs to advance DUB-targeting therapiesUbiquigent and Alleo Labs announced a strategic partnership to advance DUB-targeting therapies, combining Alleo's AI-based drug discovery with Ubiquigent's DUB expertise. The deal grants exclusive access to Alleo's RubDUB software and Ubiquigent's platforms, with financial terms undisclosed. Both companies will also collaborate with third parties developing DUB-modulating therapeutics.News-MedicalUbiquigent appoints Dr Xavier Jacq to Scientific Advisory BoardUbiquigent appointed Dr Xavier Jacq to its Scientific Advisory Board, chaired by Professor Sir Philip Cohen. He previously co-founded Mission Therapeutics and held roles at Almac and Dunad, with over 22 years in DUB drug discovery. The appointment aims to strengthen Ubiquigent's expertise in deubiquitinase modulators.PR NewswireMedivir enters into licensing agreement with Ubiquigent for preclinical program USP7Medivir AB has granted Ubiquigent Limited an exclusive worldwide license to develop and commercialize Medivir's preclinical USP7 research program, which targets a deubiquitylating enzyme linked to cancer. Under the terms of the agreement, Medivir will receive revenue share upon successful development or commercialization by Ubiquigent. The agreement builds on an existing long-term relationship between the two companies, with Medivir believing Ubiquigent is well-positioned to progress the USP7 program through its established track record in the DUB field.news.cision.comMedivir enters into licensing agreement with Ubiquigent for preclinical program USP7Medivir AB entered a licensing agreement with Ubiquigent for its preclinical USP7 research program, granting Ubiquigent an exclusive worldwide license to develop and commercialize the program. In return, Medivir receives an agreed revenue share upon successful development or commercialization by Ubiquigent.VC News DailyUbiquigent Raises 500K POUNDSUbiquigent Limited, a Dundee-based drug discovery company specializing in ubiquitin cell-signalling systems, has secured £0.5 million in funding from IP Group plc and the Scottish Investment Bank. The investment will accelerate the development and commercialisation of the company's drug discovery platforms and reagent services targeting the ubiquitin system across oncology, neurodegeneration, and cardiovascular therapeutic areas. The company has also appointed Dr Mark Treherne, a veteran biotech entrepreneur with over 25 years of industry experience, as a Non-Executive Director.